Great news today from portfolio company Microbiotica , which has announced it has received regulatory approvals in the EU and UK to initiate Phase 1b clinical studies for its live biotherapeutic products (LBPs) in advanced melanoma (MELODY-1: MB097) and ulcerative colitis (COMPOSER-1: MB310). Congratulations to the whole team on this huge milestone! Read more here: https://bit.ly/4e11tiS #biotech #melanoma #ulcerativecolitis
IP Group plc’s Post
More Relevant Posts
-
🌟The Upcoming MCE Webinar on 19 September 2024🌟 📢 MCE Webinar - New Oncology Targets from Fragment Leads 🔔 September 19, 2024 10:00 EDT / 15:00 BST / 16:00 CEST In this webinar, you will learn: ⭐ A novel fragment-based drug discovery ⭐ The development of p53 activators ⭐ The high-throughput exploration of crude reaction mixtures through automated chemistry and X-ray crystallography 👇 Click the link below to learn more about this webinar: https://lnkd.in/ejn5__Y4 #MCE #Medchemexpress #Webinar #Oncology #Fragmentleads #drugdiscovery #P53 #P53protein
-
-
When she is not busy with her #music, Rose Satz is changing the world of #radiopharmaceuticals, one of the #hottest #drug development topics for #investment at #jpm2024. Extraordinary individuals making impossible things possible! #femaleleadership #CEO #drugdevelopment #cancer #pharma #biotech
-
-
Nonclinical SME (LO to EOP1) - Creatively Prosecuting Science. Funder/Board Member/Entrepreneur/Mentor/Corporate Strategy and Escape Velocity Calculations Scilosopher at large - Pick a topic Opinions are mine alone.
A great article from a fantastic team. hERG a liability?? can you design beyond it - YES with the right team. Herein, we describe the discovery of darovasertib (NVP-LXS196), a potent pan-PKC inhibitor with high whole kinome selectivity. The lead series was optimized for kinase and off target selectivity to afford a compound that is rapidly absorbed and well tolerated in preclinical species. LXS196 is being investigated in the clinic as a monotherapy and in combination with other agents for the treatment of uveal melanoma (UM), including primary UM and metastatic uveal melanoma (MUM). https://lnkd.in/gbmFhDE6.
-
Check out Neo’s lite paper demonstrating the prevelance of RET fusions across 18 tumor types #rwd #precisionmedicine #precisiononcology
NeoGenomics is pleased to share a newly released lite paper, “Examining RET Fusions: How Real-World Data (RWD) can be used to support a Tumor-Agnostic Era.” In recent years, the FDA has approved specific therapies that are of high interest due to their potential applications in a tumor-agnostic setting. As precision oncology moves toward a targeted pan-tumor paradigm, an understanding of prevalence rates and testing patterns is critical for commercial execution and uptake. Visit us online to learn more: https://lnkd.in/e86mB_8Q
-
-
What is the projected growth in the global markets for oncology/cancer drugs and cell cryopreservation between 2023 and 2024? In 2023, the global market for #oncology/ #cancerdrugs was valued at $166,721.95 million, growing to $179,477.44 million in 2024. Similarly, the #cellcryopreservation market increased from $12,555.6 million in 2023 to $15,319.1 million in 2024, reflecting significant advancements in medical technologies and a heightened focus on innovative #healthcare solutions. #AMR #CellCryopreservation #OncologyMarket #HealthcareInnovation #MedicalResearch #Biotechnology #CancerTherapies #GlobalHealth #BiomedicalScience
-
-
Merck Features 10 Years Data from the P-III (KEYNOTE-006) Trial of Keytruda in Advanced Melanoma Patients at ESMO 2024 #merck #keytruda #melanoma #clinicaltrial #phase3 #keynote006 #esmo2024 #keynote006
Merck Highlights 10 Years Data from the P-III (KEYNOTE-006) Study of Keytruda in Advanced Melanoma Patients at ESMO 2024
pharmashots.com
-
Physiomics plc’ Virtual Tumour™ QSP model allows simulations of different drug administrations to be quickly made and the best schedule regimen chosen for further testing in vivo. 💡💊 Our model offers a versatile and cutting-edge approach for predicting and optimising schedules and combinations for a wide range of molecules, including small molecules and biotherapy. By prioritising the most effective drug combinations, our model helps you avoid costly trial-and-error approaches when determining the best administration schedules. Curious about how we can assist you in de-risking and accelerating your drug development pipeline? Find out more: https://lnkd.in/e5WVtecd #Cancer #DrugDevelopment #Insilico #VirtualTumour #TranslationalModelling #CancerDrugs #CancerSimulation #CombinationTherapies #BioTech #Pharma #PYC
-
With over 25 years of experience in research, technology, and biotech, Noelle Gaskill of Mirati Therapeutics approaches the challenges of DCTs with a comprehensive perspective, prioritizing listening to research sites. Get a sneak peek into her #ACRP2024 session, where she shares tactical insights from collaborating with thought-leaders, regulators, and sites, aiming to launch a hybrid DCT interventional oncology trial this year. Learn more about Noelle's session in Anaheim > https://bit.ly/3T5ahLX #GoForIt #GoForEducation #ClinicalTrials #ClinicalResearch #ClinicalTrialDesign #DCT #DecentralizedClinicalTrials
-
The Accent team is headed to San Diego for the #AACR24 annual meeting! We look forward to hearing the latest research in oncology and sharing new data on Accent’s first-in-class #DHX9 inhibitor and best-in-class #KIF18A inhibitor programs. We also look forward to seeing old connections and making new ones. Please contact us at contactus@accenttx.com and collaborations@accenttx.com if you’re interested in meeting with the Accent team during the meeting! #biotech #cancerresearch #precisiononcology #biotech #cancerresearch #precisiononcology
-
-
Reimagining Tumor Micro Environment science with multimodal signals generated by perturbing tumors in their near native form. Farcast celebrates processing 25,000 live human tumors, aiding cancer patients and empowering the pharmaceutical industry with trusted biosignatures. #TumorMicroEnvironment #ComputationalScience #CancerResearch #Farcast #Biosignatures
